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Abstract
Objectives: This study compared the relative cost-effectiveness of daily recombinant human deoxyri-
bonuclease (rhDNase), with alternate day rhDNase and hypertonic saline (HS) for treating children with
cystic fibrosis (CF).
Methods: A randomized controlled trial with a crossover design allocated 40 CF children consecutively
to 12 weeks of daily rhDNase, alternate day rhDNase, or HS. The primary outcome measure was
forced expiratory volume in 1 second (FEV1), a measure of lung function. All health resource use was
prospectively documented for each patient and multiplied by unit costs to give a total health service cost
for each 12-week treatment period. The nonparametric bootstrap method was used to present cost-
effectiveness acceptability curves and net benefit statistics for each treatment comparison, for various
hypothetical levels of the decision maker’s ceiling ratio.
Results: Compared with HS, there was a 14% improvement in FEV1 for daily rhDNase (95% CI, 5%
to 23%), and a 12% improvement (95% CI, 2% to 22%) for alternate day rhDNase. For a ceiling ratio
of £200 per 1% gain in FEV1, the mean net benefits of daily and alternate day rhDNase compared with
HS were £1,158 (95% CI, −£621 to 2,842) and £1,188 (95% CI, −847 to 3,343), respectively; the mean
net benefit of daily compared with alternate day rhDNase was −£30 (95% CI, −£2,091 to 1,576).
Conclusions: If decision makers are prepared to pay £200 for a 1% gain in FEV1 over a 12-week period,
then on average either rhDNase strategy is cost-effective.
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Cystic fibrosis (CF) is the most common autosomal recessive disorder of Caucasians. New
therapies have improved life expectancy in CF, but have also increased healthcare costs.
Clinical trials of recombinant human deoxyribonuclease (rhDNase) have shown improve-
ments in lung function (19). However, rhDNase is an expensive therapy, costing around
£7,500 per patient per year, and not all patients benefit from it (8). This suggests that there
is a need for economic evaluations that give information on the relative cost-effectiveness of
rhDNase compared with other treatment strategies for CF, such as hypertonic saline (HS).
Previous health technology assessments for CF have applied cost-consequence analysis
to compare treatment strategies. Oster et al. (15) used data from a U.S. clinical trial that
compared the effectiveness of rhDNase with placebo in adults with CF (8). However, this
study excluded the cost of rhDNase and only assessed respiratory tract infection–related
health costs. The study suggested that rhDNase (administered once or twice daily) improved
patients’ lung function and reduced hospitalizations, which could potentially offset around
25% of the drug’s cost. Menzin et al. (12) used data from the same U.S. trial to compare
the costs of rhDNase with placebo in four different European countries. The analysis used
expert opinion to adapt the resource use observed in the trial to a European context, and
concluded that rhDNase could reduce health service costs by between US $700 and $1,000
over 6 months. The validity of the latter study was limited by the extent to which data could
be transferred between the United States and Europe.
A U.K. study has recently compared the effectiveness and costs of treating children
with CF with daily rhDNase (2.5 mg), alternate day rhDNase (2.5 mg) and HS (21). The
study was based on a randomized controlled trial with a crossover design, with 40 patients
receiving each treatment for 12 weeks, with a 2-week washout period between treatments
(22). The primary outcome measure was the patients’ lung function measured by forced
expiratory volume in 1 second (FEV1). Comparing mean FEV1 between the treatments,
the trial reported an 8% (95% CI, 2% to 14%, p = .01) advantage for daily rhDNase over
HS, but none for daily compared with alternate day rhDNase (2%, 95% CI, −4% to 9%,
p = .55) (22).
The aim of this paper is to extend this analysis and estimate the relative cost-effectiveness
of daily rhDNase, alternate day rhDNase, and HS for children with CF over a 12-week pe-
riod. This requires costs and effects to be reported using a summary measure such as the
incremental cost-effectiveness ratio (ICER). However, difficulties surrounding the measure-
ment and interpretation of statistical uncertainty with ICERs have been well documented
(2;4;14;16). To avoid these problems, alternative measures of cost-effectiveness, including
the cost-effectiveness acceptability curve (CEAC) and net benefit statistic (NB), have been
developed (20;23). This paper illustrates the use of these alternative techniques using data
from the U.K. cross-over trial described above.
METHODS
A cost-consequence analysis of the respective treatment strategies was specified in the orig-
inal study protocol, and the methodology has been detailed elsewhere (21). To summarize,
all healthcare resource use was measured for every patient included in the study over each
treatment period. The resource use included hospital contacts (inpatient, outpatient, and
day case), radiological investigations, blood tests, drugs, and the use of community ser-
vices (including community nurse, physiotherapist, and general practitioner). Data were
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recorded from the patients’ hospital notes, discharge letters, and by contacting the super-
vising physicians.
Unit costs of health services were collected at the two postgraduate hospitals where
patients were recruited and from a local district general hospital. Drug costs were taken
from the British National Formulary (BNF) (5), and community care costs from Netten et al.
(13). All costs were adjusted to 1999–2000 prices using the hospital and community health
services price index (9). Total costs for each treatment period were calculated by multiplying
each patient’s resource use by the appropriate unit cost. In the baseline analysis, the unit
costs were from the specific study hospitals and the drug costs taken from the BNF.
The effectiveness of each of the treatment strategies was measured using the primary
outcome measure from the trial (FEV1), a measure of patients’ lung function that is as-
sociated with mortality (10;11), and has been recommended for use in studies evaluating
new treatments for CF (17). This measure was chosen in preference to measures of health-
related quality of life (HRQoL), which would have been unlikely to be sensitive to change
in treatment regimen over a 12-week period.
Statistical and Sensitivity Analysis
The aim of the analysis was to compare the relative cost-effectiveness of the three different
strategies, so that the 40 patients who had received each of the treatments were included.
This approach differed from the original trial analysis in which two separate pairwise com-
parisons, of daily rhDNase versus alternate day rhDNase (n = 43) and of HS versus daily
rhDNase (n = 40), were undertaken. All statistical analyses are based on comparisons be-
tween treatments as assessed from within-patient differences, since the trial used a crossover
design.
For each treatment period, the change in effectiveness was calculated by taking the nat-
ural logarithm of the end of treatment FEV1, yD, yA, yS, and beginning of treatment FEV1
xD, xA, xS for daily rhDNase, alternate day rhDNase, and HS, respectively. The difference
in log FEV1 (e.g., yD − xD) was calculated for each treatment period and compared be-
tween treatments. For example, the incremental effectiveness of daily versus alternate day
rhDNase, was ED−A = (yD − xD) − (yA − xA). This method of adjusting for the baseline
differed from the original trial analysis, which used analysis of covariance. The incremental
effectiveness was calculated on a log scale, which enabled the results to be interpreted in
terms of percentage differences in FEV1.
For each treatment comparison, the incremental cost was calculated as the difference
in total costs and refers to a 12-week period. The mean incremental cost was reported with
95% confidence intervals (CI) calculated using the nonparametric bootstrap (bias corrected
method) (7). For each treatment comparison, the mean ICER was calculated by dividing
the mean incremental cost by the mean incremental effectiveness, and corresponded to the
additional average cost for a 1% improvement in FEV1.
The nonparametric bootstrapping approach was used to plot the incremental costs and
effects on the cost-effectiveness plane (1), using 2,000 samples. The ceiling ratio (Rc) is
defined as the amount that the healthcare decision maker is willing to pay (2). The CEAC
shows the probability that the intervention is cost-effective for various values of Rc(2). The
CEAC was derived by plotting the proportion of the bootstrap samples that may be regarded
as cost-effective when the ceiling ratio was varied from £0 to £400 per 1% improvement in
FEV1.
The net benefits approach (NB) requires either the difference in costs or effects to be
rescaled using the ceiling ratio (Rc). Net benefits on the cost scale are defined as:
NB = Rc. ¯E −  ¯C (20).
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Net benefits were calculated for each bootstrap sample for a range of ceiling ratios from
£100 to £400 per 1% increase in FEV1. Mean net benefits were reported with 95% bootstrap
confidence intervals calculated using the bias-corrected method (7).
In the sensitivity analysis, the price of rhDNase was reduced from the BNF price by
10%–30% to assist with the generalizability of the results (3), since in practice healthcare
providers may purchase rhDNase at a lower price. Similarly, the effect of changing the cost
per hospital day was assessed to examine the impact of cost variation between providers.
RESULTS
A total of 47 children were recruited to the study. The mean age was 12.6 years (range
from 7 to 17) and 83% were taking rhDNase at enrollment. Seven patients withdrew from
one or all of the treatment periods and are excluded from the analysis (22). The mean
resource use for each of the treatment periods was similar (Table 1), and the main rea-
son for the differences in total cost was the higher unit cost of rhDNase (£20.39 per day)
compared with HS (£0.38 per day). Compared with HS, there was a 14% improvement
in FEV1 for daily rhDNase (95% CI, 5% to 23%) and a 12% improvement (95% CI, 2%
to 22%) for alternate day rhDNase. There was no significant advantage for daily com-
pared with alternate day rhDNase (2% improvement in FEV1 with 95% CI, −6% to 12%)
(Table 2).
The bootstrap samples plotted on the cost-effectiveness plane for each of the compar-
isons show the uncertainty surrounding the mean estimate of cost-effectiveness reported
Table 1. Mean (SD) Resource Use, Total Costs, and Clinical Outcomes in Three Treatment
Groups over 12 Weeks
HS Daily rhDNase Alternate day rhDNase
Hospital admissions 0.53 (0.75) 0.63 (0.87) 0.80 (1.07)
Total inpatient days (no. days) 5.13 (8.84) 4.73 (7.73) 5.65 (7.70)
Outpatient visits (no. visits) 1.23 (1.10) 0.93 (1.07) 0.83 (0.81)
GP contacts (no. contacts) 0.25 (0.49) 0.30 (0.61) 0.18 (0.38)
Nurse contacts (no. contacts) 2.70 (10.12) 1.75 (6.65) 2.38 (7.91)
Total cost (£) 4,285 (3,903) 5,694 (3,377) 5,230 (3,737)
Effectiveness (% change in FEV1)a 0 (27) 14 (27) 12 (19)
aApproximate SD.
Table 2. Mean Incremental Cost, Incremental Effectiveness, and Net Benefit over 12 Weeks
(95% CI)
Daily Daily–alternate day Alternate day
rhDNase–HS rhDNase rhDNase–HS
Total cost (£) 1,409 (354 to 2,277) 464 (−647 to 1,510) 945 (−509 to 2,301)
Effectiveness
(% FEV1) 14 (5 to 23) 2 (−6 to 12) 12 (2 to 22)
ICER (£ per 1%
gain in FEV1) 110 214 89
Mean net benefit (£)
Rc = £400 per 1%
gain in FEV1 3,725 (585 to 6,701) 403 (−3,303 to 3,341) 3,321 (−116 to 6,976)
Rc = £200 per 1%
gain in FEV1 1,158 (−621 to 2,842) −30 (−2,091 to 1,576) 1,188 (−847 to 3,343)
Rc = £100 per 1%
gain in FEV1 −126 (−1,293 to 1,041) −246 (−1,596 to 909) 121 (−1,323 to 1,752)
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by the ICER (Figure 1A–C). The problem of interpreting negative ratios is illustrated in
Figure 1B, where bootstrap samples fall in all four quadrants. Therefore an ICER of −£200
per 1% gain in FEV1 might represent improved outcomes and lower costs for daily com-
pared with alternate day rhDNase, or worse outcomes and higher costs. This means that a
meaningful ordering of the ratios, which is required to make confidence intervals around
the ICER interpretable, is impossible.
Figure 2 shows the CEAC for each of the three comparisons. If the decision maker
had a ceiling ratio of £200 per 1% gain in FEV1, the probability of daily or alternate day
rhDNase proving cost-effective, compared with HS, would be 0.91 and 0.88. For the same
ceiling ratio, the probability of daily rhDNase being cost-effective, compared with alternate
day rhDNase, is 0.49.
The mean ICER for each comparison corresponded closely to the ceiling ratio (Rc)
when the probability of one intervention being cost-effective was 0.5. The CEAC cut the
Figure 1A. Results on the cost-effectiveness plane of daily rhDNase–HS.
Figure 1B. Daily–alternate day rhDNase.
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Figure 1C. Alternate day rhDNase–HS.
Figure 2. Cost-effectiveness acceptability curves.
vertical axis at the one-sided p value for the cost difference (.001 for daily rhDNase vs HS),
and asymptotes to 1 minus the one-sided p value of the effectiveness difference (.999 for
daily rhDNase vs HS).
Assuming that Rc = £200 per 1% increase in FEV1,then the mean net benefits of daily
and alternate day rhDNase compared with HS were £1,158 (95% CI, −621 to 2,842) and
£1188 (95% CI, −847 to 3343), respectively (Table 2). At this ceiling ratio, the net benefit
of daily compared with alternate day rhDNase was −£30 (95% CI, −2,091 to 1,576).
The sensitivity analysis did not find the results sensitive to the unit costs of hospital
services, but changing the price of rhDNase was somewhat more important. For example,
the probability of daily rhDNase compared with alternate day rhDNase being cost-effective,
when Rc = £200 per 1% gain in FEV1, rose from 49% to 59% as the price of rhDNase was
reduced by 0%–30% (Figure 3).
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Figure 3. Sensitivity analysis: price of rhDNase on the CEAC of daily vs alternate day
rhDNase.
DISCUSSION
This is the first full cost-effectiveness analysis of different treatment strategies for patients
with CF. The main result was that rhDNase administered on an alternate or daily basis was
more effective than HS. If decision makers are prepared to pay £200 for a 1% increase in
FEV1 over a 12-week period, the probability of daily or alternate day rhDNase proving
cost-effective compared with HS is substantially greater than 50%. At this ceiling ratio, the
mean net benefits of daily rhDNase compared with HS are positive but with wide confidence
intervals, illustrating the uncertainty that surrounds these results.
In the United Kingdom, children with CF who have moderate to severe lung disease
are routinely prescribed daily rhDNase. This study suggests it may be more cost-effective
if rhDNase is prescribed on an alternate-day basis. Unless decision makers are willing
to pay over £200 per 1% FEV1 gained, the probability of daily rhDNase proving more
cost-effective than alternate day rhDNase is less than 50%, and the mean net benefit is
negative.
This study extends previous studies in this area by presenting detailed information
on hospital and community health service resources and by including information on the
cost of the interventions. The results show that while rhDNase improves outcomes, this
is at an increased cost. In such circumstances, a full cost-effectiveness analysis was able
to summarize the results using a single measure of cost-effectiveness. This work therefore
extends the cost-consequence analyses previously published (15;21) and indicates clearly
the trade-offs involved when choosing between competing interventions (6).
As this is the first study to present a full cost-effectiveness analysis for CF, the possibility
of comparing the results to other competing interventions is limited, and the decision makers’
ceiling ratio is unknown. Further studies are needed to assess the cost-effectiveness of
new high-cost interventions for CF (for example, nebulized TOBI Chiron, Emeryville,
California, USA., [18]). In order to facilitate comparison between interventions, future
studies need to use the same measures of cost-effectiveness.
One limitation of the study is the narrowness of the outcome measure used, which
limits comparisons of cost-effectiveness to other studies evaluating therapies in CF or other
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lung diseases. The objective of the study was to provide decision makers with information
on how best to allocate resources within this particular disease area, rather than across a
range of healthcare interventions. To facilitate broader comparisons, a generic measure of
outcome such as the quality-adjusted life-year (QALY) would have been needed. While the
study did collect information on quality of life using a disease-specific measure, it was not
possible to use this measure to derive QALY values.
This study is a rare example of a full economic evaluation alongside a crossover trial.
This raised certain methodologic issues, in particular that all the results are based on paired
differences within patients, which increases statistical efficiency. The method used to mea-
sure outcomes in the economic evaluation compared the between-treatment differences in
outcome by subtracting the start of treatment FEV1 from the end of treatment FEV1 on a
logged scale. This method adjusted for baseline values and provided results that could be
used in the bootstrapping procedure required for the cost-effectiveness analysis. In the trial,
analysis of covariance was used to provide baseline-adjusted outcome measures, but could
not so easily be used as a basis for a cost-effectiveness analysis. The different methods
produced somewhat different estimates of incremental effectiveness.
While this study reported measures of uncertainty around the cost-effectiveness mea-
sures based on the resource use and outcomes data observed in the study, other uncertainties
exist that warrant further investigation. In particular, the examination of the impact of varying
unit costs has been limited to deterministic sensitivity analysis. Further work will exam-
ine the extent to which incorporating statistical measures of uncertainty in unit costs may
change the estimation of the magnitude of uncertainty surrounding the cost-effectiveness
results.
POLICY IMPLICATIONS
If decision makers are prepared to pay £200 for a 1% gain in FEV1 (or £2,000 for a 10% gain)
over a 12-week period, then either rhDNase strategy on average has positive net benefits
compared with HS and should be adopted. This study suggests that providing rhDNase
on an alternate-day basis may be the more cost-effective alternative. This evaluation did
not find that daily rhDNase improves patient’s lung function compared with alternate day
rhDNase, and the total health service cost of alternate day rhDNase was on average about
£500 lower over 12 weeks. Assuming that the pattern of health service use was maintained
over a year, moving to alternate day rhDNase could lead to a reduction in annual health
service costs of about £2,000 per patient.
This paper used appropriate measures of cost-effectiveness, the net benefit statistic,
and cost-effectiveness acceptability curve in the context of a crossover trial. The use of
these measures provided a further illustration of the uncertainty that surrounds the results
of cost-effectiveness analyses. In this study, although alternate day rhDNase was associated
with lower average total costs and similar outcomes to daily rhDNase, the confidence
intervals around the average net benefit spanned zero for various levels of the ceiling ratio.
This suggests that to establish that alternate-day rhDNase is more cost-effective than daily
rhDNase, a larger study would be required.
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